Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Estee Lauder Companies Cl A / Equity Bottom-Up

<ul><li>Estée Lauder Companies recently reported its Q1 Fiscal 2025 earnings and the financial results revealed mixed dynamics, characterized by challenges and strategic initiatives aimed at overcoming them.</li><li>The company reported a 5% decrease in organic sales, primarily driven by significant declines in Mainland China, global travel retail, and Hong Kong SAR.</li><li>Conversely, when excluding these markets, sales in other global business areas saw an increment of 1%.</li></ul>

Estée Lauder Companies recently reported its Q1 Fiscal 2025 earnings and the financial results revealed mixed dynamics, characterized by challenges and strategic initiatives aimed at overcoming them.The company reported a 5% decrease in organic sales, primarily driven by significant declines in Mainland China, global travel retail, and Hong Kong SAR.Conversely, when excluding these markets, sales in other global business areas saw an increment of 1%.

The Estee Lauder Companies: Will Its Focus on Brand Building & Market Share Expansion Be A Breakthrough Move? - Major Drivers

<ul><li>Estée Lauder Companies' fiscal 2024 results reflect a challenging environment particularly impacted by market conditions in China and the Asia-Pacific region.</li><li>The fiscal year witnessed a 2% contraction in organic sales, with a modest gross margin expansion and a decline in adjusted operating margin by 120 basis points to 10.2%.</li><li>The company's performance in various regions displayed disparity, with noted declines in Mainland China contrasted by growth in EMEA (Europe, the Middle East, and Africa) primarily due to a recovery in Asia travel retail.</li></ul>

Estée Lauder Companies' fiscal 2024 results reflect a challenging environment particularly impacted by market conditions in China and the Asia-Pacific region.The fiscal year witnessed a 2% contraction in organic sales, with a modest gross margin expansion and a decline in adjusted operating margin by 120 basis points to 10.2%.The company's performance in various regions displayed disparity, with noted declines in Mainland China contrasted by growth in EMEA (Europe, the Middle East, and Africa) primarily due to a recovery in Asia travel retail.

Estée Lauder Companies: A Tale Strategic Pricing & Precision Marketing! - Major Drivers

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

<ul>
<li>Giant Biogene was listed in Hong Kong IPO in 2022. It has done well since and is now trading 45% above its IPO price, but its still cheap.</li>
<li>GB is a leader in the bioactive ingredient-based professional skin treatment product industry in China.</li>
<li>In this note, we will talk about the company’s past performance and future prospects.</li>
</ul>


Giant Biogene was listed in Hong Kong IPO in 2022. It has done well since and is now trading 45% above its IPO price, but its still cheap.
GB is a leader in the bioactive ingredient-based professional skin treatment product industry in China.
In this note, we will talk about the company’s past performance and future prospects.


2024 High Conviction - Giant Biogene - Growth Rate Keeps Moving Higher

Analyst

Steve

<ul>
<li>
<a href="https://www.smartkarma.com/entities/l-occitane-international-sa" target="_blank" data-smartkarma-citation="entities:6772:1" rel="noopener">L'Occitane (973 HK)</a> announced after market close yesterday that the controlling shareholder has terminated the potential general offer. </li>
<li>Shares trade at a significant discount to global cosmetics peers and its own historical trading range, while brands' growth momentum remain intact. </li>
<li>Take advantage of any potential significant sell-down caused by the drop of the privatization attempt. </li>
</ul>



L'Occitane (973 HK) announced after market close yesterday that the controlling shareholder has terminated the potential general offer. 
Shares trade at a significant discount to global cosmetics peers and its own historical trading range, while brands' growth momentum remain intact. 
Take advantage of any potential significant sell-down caused by the drop of the privatization attempt. 


L'Occitane (973 HK):  Underlying Fundamentals Intact

<ul><li>The third-quarter fiscal results of The Estée Lauder Companies showcased a strong performance, marked by an inflection point demonstrating a renewed sales and profit growth trajectory.</li><li>The top-line numbers saw an organic sales growth of 6%, thereby meeting the firm's high range outlook.</li><li>The company also reported exceeding expectations in terms of profitability and improving working capital significantly.</li></ul>

The third-quarter fiscal results of The Estée Lauder Companies showcased a strong performance, marked by an inflection point demonstrating a renewed sales and profit growth trajectory.The top-line numbers saw an organic sales growth of 6%, thereby meeting the firm's high range outlook.The company also reported exceeding expectations in terms of profitability and improving working capital significantly.

The Estée Lauder Companies: What Is Their  Profit Recovery Plan For Sales Growth & Profitability? - Major Drivers

United States

The Estee Lauder Companies Inc. manufactures and markets a wide range of skin care, makeup, fragrance, and hair care products.  The Company's products are sold in countries and territories around the world.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Estee Lauder Companies Cl A (EL US)

Estée Lauder Companies: A Tale Strategic Pricing & Precision Marketing! - Major Drivers

Estée Lauder Companies' fiscal 2024 results reflect a challenging environment particularly impacted by market conditions in China and the...

Baptista Research

2024 High Conviction - Giant Biogene - Growth Rate Keeps Moving Higher

Giant Biogene was listed in Hong Kong IPO in 2022. It has done well since and is now trading 45% above its IPO price, but its still cheap.

Sumeet Singh

L'Occitane (973 HK): Underlying Fundamentals Intact

L'Occitane (973 HK)'s controlling shareholder terminates potential privatization offer, but the company's growth prospects remain strong. Take...

Steve

The Estée Lauder Companies: What Is Their Profit Recovery Plan For Sales Growth & Profitability? - Major Drivers

The third-quarter fiscal results of The Estée Lauder Companies showcased a strong performance, marked by an inflection point demonstrating a...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

The Estee Lauder Companies: Will Its Focus on Brand Building & Market Share Expansion Be A Breakthrough Move? - Major Drivers

Estée Lauder Companies recently reported its Q1 Fiscal 2025 earnings and the financial results revealed mixed dynamics, characterized by...

Baptista Research

Estée Lauder Companies: A Tale Strategic Pricing & Precision Marketing! - Major Drivers

Estée Lauder Companies' fiscal 2024 results reflect a challenging environment particularly impacted by market conditions in China and the...

Baptista Research

2024 High Conviction - Giant Biogene - Growth Rate Keeps Moving Higher

Giant Biogene was listed in Hong Kong IPO in 2022. It has done well since and is now trading 45% above its IPO price, but its still cheap.

Sumeet Singh

L'Occitane (973 HK): Underlying Fundamentals Intact

​L'Occitane (973 HK)'s controlling shareholder terminates potential privatization offer, but the company's growth prospects remain strong. Take...

Steve

The Estée Lauder Companies: What Is Their Profit Recovery Plan For Sales Growth & Profitability? - Major Drivers

The third-quarter fiscal results of The Estée Lauder Companies showcased a strong performance, marked by an inflection point demonstrating a...

Baptista Research

L'Occitane (973 HK)'s controlling shareholder terminates potential privatization offer, but the company's growth prospects remain strong. Take...